On July 6, 2023 IngenOx Therapeutics, IngenOx Therapeutics, an Oxford-based clinical-stage biopharma company, reported that it has been granted patents for new compounds that inhibit PRMT5 (Press release, IngenOx Therapeutics, JUL 6, 2023, View Source [SID1234633081]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new patents are for the composition of matter for AT101, the focus of IngenOx’s clinical PRMT5 inhibitor programme.

This is in addition to the granted patents by the US patent office (US11485731B2) granted in November 2022 by the US Patent and Trademark Office (USPTO), the Japan patent (JP7211982B2) granted in January 2023 by the Japan Patent Office (JPO), and the Singapore patent (SG11201908598) granted in May 2023 by the Intellectual Property Office of Singapore (IPOS).

The invention relates to compounds suitable for the inhibition of protein arginine methyltransferase (PRMT), in particular PRMT5. These compounds may be used as therapeutic agents for use in the treatment of/or prevention of proliferative diseases, such as cancer.

Nick La Thangue, CEO of IngenOx, and Professor of Cancer Biology at the University of Oxford commented:"We are delighted to receive these newly granted international patents. This highlights the innovation driving IngenOx’s growth and enables us to creatively differentiate ourselves in the PRMT5 field. Moving ahead, we will profile our lead PRMT5 inhibitor, AT101, in clinical studies and seek to achieve therapeutic benefits for patients suffering with clinically unmet cancers."